Stock Updates

How has Alexion Pharmaceuticals, Inc.:(NASDAQ:ALXN) performed recently?

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) is a large market cap stock with a market cap of 28125.41. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 317.75, a forward P/E of 21.48 and EPS of 0.4. At a stock price of 125.51 (1.70%) it has a dividend yield of *TBA.

EPS growth for the last five years have been 5.10%, more recently this last year it has grown by -79.50%. The next year growth is going to be about 25.04% and more long-term 18.28% after five years. EPS growth quarter over quarter is -38.80%. Sales growth for the past five years have been 36.90% and sales growth quarter over quarter is 18.40%.

For performance, Alexion Pharmaceuticals, Inc. the past week has seen a gain of 1.41%. For the last month performance for Alexion Pharmaceuticals, Inc. is -0.27%. While the last quarter is 1.76% and half year, -15.21%. Finally for the year, performance is -21.56%.

The 52-week high for Alexion Pharmaceuticals, Inc., is at -35.12%, and for the 52-week low it comes to a value of 13.52%. The 20-day simple moving average is -3.40% and -11.03% for the 200-day simple moving average.

Volatility for the week is at 2.87%, and for the month it is 3.10%. Alexion Pharmaceuticals, Inc., has a target price of 164.11.

In terms of debt, long term debt/equity is 0.39, and for total debt/equity Alexion Pharmaceuticals, Inc. has 0.4. The gross margin is 91.80%, while operating margin is 21.70%, the profit margin is 3.20%. The current ratio is 3.6 and the quick ratio is 3.1.

Insider ownership is at 0.50%, with instituitional ownership at 98.30%. Alexion Pharmaceuticals, Inc. has a payout ratio of 0.00%. With the total shares outstanding coming to 224.09. The shares float is 223.44, with the float short at 2.18%, with short ratio coming to 3.19.

In terms of returns, the return on assets see Alexion Pharmaceuticals, Inc., get 0.70%, with its returns on investment at 1.60%. Return on equity is 1.10%. So will the investors see the target price of 164.11, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Tony Dabbs

Leave a Comment